Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas

Last updated:
2026-07-18
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A RANDOMIZED PHASE III TRIAL OF DOXORUBICIN + PEMBROLIZUMAB VERSUS DOXORUBICIN ALONE FOR THE TREATMENT OF UNDIFFERENTIATED PLEOMORPHIC SARCOMA (UPS) AND RELATED POORLY DIFFERENTIATED SARCOMAS

Intervention/treatment:
KEYTRUDA
Medical condition:
SARCOMA
Protocol code:
SRC.8 / EA7222
Control number:
290821
Status:
Recruiting
Approved:
October 30, 2024
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT06422806
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years and older
Accepts healthy volunteers: No

Contacts and locations

Contact
Sponsor
CANADIAN CANCER TRIALS GROUP, CANCER RESEARCH INSTITUTE, QUEEN'S UNIVERSITY

Locations

Alberta

Arthur J E Child Comprehensive Cancer Centre
Calgary, Alberta, T2N 5G2
RECRUITING
Name
Site Public Contact
Role
CONTACT
Phone:
888-823-5923
Name
Xiaolan Feng
Role
PRINCIPAL_INVESTIGATOR
Cross Cancer Institute
Edmonton, Alberta, T6G 1Z2
RECRUITING
Name
Site Public Contact
Role
CONTACT
Phone:
780-432-8500
Name
Quincy S. Chu
Role
PRINCIPAL_INVESTIGATOR

British Columbia

BCCA-Vancouver Cancer Centre
Vancouver, British Columbia, V5Z 4E6
RECRUITING
Name
Site Public Contact
Role
CONTACT
Phone:
888-939-3333
Name
Jamie Feng
Role
PRINCIPAL_INVESTIGATOR

Manitoba

CancerCare Manitoba
Winnipeg, Manitoba, R3E 0V9
RECRUITING
Name
Site Public Contact
Role
CONTACT
Phone:
866-561-1026
Name
Shantanu Banerji
Role
PRINCIPAL_INVESTIGATOR

Ontario

Juravinski Cancer Centre at Hamilton Health Sciences
Hamilton, Ontario, L8V 5C2
RECRUITING
Name
Site Public Contact
Role
CONTACT
Phone:
905-387-9495
Name
Courtney Coschi
Role
PRINCIPAL_INVESTIGATOR
Ottawa Hospital and Cancer Center-General Campus
Ottawa, Ontario, K1H 8L6
RECRUITING
Name
Site Public Contact
Role
CONTACT
Phone:
613-761-4395
Name
Garth A. Nicholas
Role
PRINCIPAL_INVESTIGATOR
University Health Network-Princess Margaret Hospital
Toronto, Ontario, M5G 2M9
RECRUITING
Name
Site Public Contact
Role
CONTACT
Phone:
416-946-4501
Name
Abdulazeez Salawu
Role
PRINCIPAL_INVESTIGATOR

Quebec

CHU de Quebec-L'Hotel-Dieu de Quebec (HDQ)
Québec, Quebec, G1R 2J6
RECRUITING
Name
Site Public Contact
Role
CONTACT
Name
Christopher Lemieux
Role
PRINCIPAL_INVESTIGATOR
Did you find what you were looking for?